Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has been assigned a consensus recommendation of “Moderate Buy” from the four brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $37.50.

A number of brokerages have recently commented on INTS. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. Finally, Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in Intensity Therapeutics by 77.8% during the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after purchasing an additional 201,357 shares during the period. Legacy Advisors LLC purchased a new stake in Intensity Therapeutics in the 4th quarter worth approximately $63,000. State Street Corp lifted its holdings in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after buying an additional 121,700 shares during the period. Corient Private Wealth LLC bought a new stake in shares of Intensity Therapeutics in the 4th quarter worth approximately $41,000. Finally, Jane Street Group LLC bought a new stake in shares of Intensity Therapeutics in the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Stock Performance

Shares of NASDAQ INTS traded down $0.09 during midday trading on Tuesday, hitting $4.20. The company’s stock had a trading volume of 26,259 shares, compared to its average volume of 43,618. The stock has a fifty day moving average price of $4.24 and a 200 day moving average price of $5.68. Intensity Therapeutics has a one year low of $3.51 and a one year high of $43.50. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $11.34 million, a price-to-earnings ratio of -0.74 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, research analysts forecast that Intensity Therapeutics will post -2.7 EPS for the current fiscal year.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.